EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access

Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study

Izuki Ogawa, Takuma Narita iD, Masanao Shinohara, Yohei Kawashima, Yuya Sekine, Shintaro Narita iD, Shin Kobayashi, Noriyuki Abe iD, Shunsuke Tazawa, Naoki Fujita iD, Jotaro Mikami, Teppei Okamoto iD und 6 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70636 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Izuki Ogawa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Carcinoma, Transitional Cell, Neoplasm Recurrence, Local, Nivolumab. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe post‐recurrence treatment patterns and outcomes after adjuvant nivolumab for urothelial carcinoma in real‐world practice.

Methods

We retrospectively analyzed patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy followed by adjuvant nivolumab in the multicenter AGEHA database. Among 141 patients, 40 developed recurrence, excluding non‐muscle‐invasive bladder recurrence. First‐line post‐recurrence treatment was categorized as enfortumab vedotin plus pembrolizumab (EVP), enfortumab vedotin (EV), non‐EV regimens, or no systemic therapy. Overall survival (OS) was measured from recurrence and progression‐free survival (PFS) from initiation of first‐line post‐recurrence therapy.

Results

Of 141 patients treated with adjuvant nivolumab, 40 (28%) developed recurrence. First‐line post‐recurrence treatment was EVP in 10 patients, EV in 15, non‐EV regimens in 12, and no systemic therapy in 3. Median time from surgery and nivolumab initiation to recurrence was 5.9 and 4.2 months, respectively. Median OS from recurrence was 27.1, 26.0, and 23.4 months in the EVP, EV, and non‐EV groups, respectively, while median PFS from initiation of first‐line post‐recurrence therapy was 12.9, 7.6, and 8.7 months. Baseline characteristics differed across groups, particularly in recurrence timing and metastatic sites, and EV‐based therapy was frequently selected after recurrence.

Conclusions

Recurrence after adjuvant nivolumab occurred in 28% of patients in real‐world practice. Post‐recurrence management was heterogeneous, and EV‐based therapy was frequently used in this setting. These findings provide hypothesis‐generating real‐world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalCarcinoma, Transitional CellNeoplasm Recurrence, LocalNivolumabUrinary Bladder NeoplasmsAgedAged, 80 and overFemaleHumansMaleMiddle AgedChemotherapy, AdjuvantCystectomyNephroureterectomyProgression-Free SurvivalRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal

Stichwörter der Autor:innen

adjuvant nivolumabenfortumab vedotinradical cystectomyradical nephroureterectomytreatment sequencingurothelial carcinoma

Substanzen

Antineoplastic Agents, Immunologicalenfortumab vedotinNivolumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Ageo Central General Hospital, Ageo, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Asahikawa Medical University, Asahikawa, Japan.
  • Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Department of Advanced Transplant and Regenerative Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

ORCID-Profile: Takuma Narita, Shintaro Narita, Noriyuki Abe, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Kazuyuki Numakura, Shingo Hatakeyama

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Ogawa, I., Narita, T., Shinohara, M., Kawashima, Y., Sekine, Y., Narita, S., Kobayashi, S., Abe, N., Tazawa, S., Fujita, N., Mikami, J., Okamoto, T., Yamamoto, H., Numakura, K., Sato, S., Habuchi, T., Ohyama, C., & Hatakeyama, S. (2026). Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study. International Journal of Urology. https://doi.org/10.1111/iju.70636

Vancouver

Ogawa I, Narita T, Shinohara M, Kawashima Y, Sekine Y, Narita S, et al. Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study. International Journal of Urology. 2026. doi:10.1111/iju.70636

BibTeX
@article{Ogawa2026,
  author = {Ogawa, Izuki and Narita, Takuma and Shinohara, Masanao and Kawashima, Yohei and Sekine, Yuya and Narita, Shintaro and Kobayashi, Shin and Abe, Noriyuki and Tazawa, Shunsuke and Fujita, Naoki and Mikami, Jotaro and Okamoto, Teppei and Yamamoto, Hayato and Numakura, Kazuyuki and Sato, Satoshi and Habuchi, Tomonori and Ohyama, Chikara and Hatakeyama, Shingo},
  title = {Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real‐World Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70636}
}
Kostenlos starten →